We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
FDA approved durvalumab with BCG for high-risk NMIBC. POTOMAC data: 32% risk reduction. Analysis of efficacy, toxicity, and consequences of BCG shortage. Learn more.